Pancreatic Cancer Research

ResearcherPeking University First HospitalActive in the last 2 years

Yingjin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9166-0009; OpenAlex author ID A5075677773. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

  1. Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis. Co-author DOI 10.1002/advs.75216↗
  2. Multi-omics analysis of polyamine metabolism implicates NT5E/CD73 in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217887↗
  3. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis. Co-author DOI 10.1007/s10238-023-01112-2↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongsu Ma · 3 shared papers, 2023–2026 · strength 0.66
  2. Yinmo Yang · 2 shared papers, 2023–2026 · strength 0.46
  3. Xiaodong Tian · 1 shared paper, 2026 · strength 0.27
  4. Baoyi Li · 1 shared paper, 2025 · strength 0.20
  5. Enkui Zhang · 1 shared paper, 2025 · strength 0.20
  6. Mingzhe Li · 1 shared paper, 2025 · strength 0.20
  7. Xiaodong Tian · 1 shared paper, 2025 · strength 0.20
  8. Yinmo Yang · 1 shared paper, 2025 · strength 0.20
  9. Bohan Yang · 1 shared paper, 2023 · strength 0.18
  10. Long Di · 1 shared paper, 2023 · strength 0.18
  11. Weikang Liu · 1 shared paper, 2023 · strength 0.18
  12. Xiaodong Tian · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.